3 min read The GLP-1 landscape changed on 1 April 2026, when the FDA approved Eli Lilly's orforglipron under the brand name Foundayo as the first non-peptide, small-molecule GLP-1 receptor agonist (GLP-1RA) anywhere in the world
To further investigate which CD4 + T-cell subpopulation was modulated, we analyzed the Ly5.2 + Th1, Th2, and Th17 T cells
You can have the product you bought from us tested at any HPLC licensed testing facility and if the results are negative, we will refund the following: HPLC TEST FEE $100 PLUS Total amount of the Order + Shipping Fee
Unlike true peptides, Dihexa is not degraded by peptidases, has a relatively small molecular weight (~480 Da), and crosses the blood-brain barrier efficiently after systemic administration
A Weill Cornell post-hoc analysis of SURMOUNT trial data found that tirzepatide produced approximately 20 percent weight reduction in women regardless of whether they were premenopausal, perimenopausal, or postmenopausal